Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer

被引：2
|
作者：
Nauseef, Jones T.
Sun, Michael
Thomas, Charlene
Bissassar, Mahelia
Fernandez, Escarleth
Davidson, Zachary
Patel, Amie
Tan, Angela
Chamberlain, Tessa A.
Earle, Kara
Wunder, Rebecca
Guervil, Sabrina
Castellanos, Sandra H.
Stangl-Kremser, Judith
Gregos, Peter S.
Osborne, Joseph R.
Ballman, Karla V.
Molina, Ana M.
Sternberg, Cora N.
Nanus, David M.
Bander, Neil H.
Tagawa, Scott T.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT014
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Vallabhajosula, Shankar
    Jhanwar, Yuliya
    Ballman, Karla V.
    Hackett, Amy
    Emmerich, Lauren
    Babich, John
    Sartor, A. Oliver
    Harshman, Lauren Christine
    Beltran, Himisha
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [2] A phase I/II dose-escalation study of fractionated and multiple dose 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
    Sun, Michael
    Nauseef, Jones T.
    Lebenthal, Justin M.
    Niaz, Muhammad Junaid
    Singh, Sharon
    Chamberlain, Tessa A.
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Vallabhajosula, Shankar
    Babich, John
    Christos, Paul J.
    Osborne, Joseph
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, Scott T.
    Osborne, Joseph
    Niaz, Muhammad Junaid
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Thomas, Charlene
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Fernandez, Escarleth
    Babich, John
    Nanus, David M.
    Ballman, Karla V.
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Sun, Michael
    Nauseef, Jones
    Fajardo, Andres Ricaurte
    Davidson, Zachary
    Thomas, Joseph
    Ruder, Samuel
    Stangl-Kremser, Judith
    Castellanos, Sandra Huicochea
    Molina, Ana
    Sternberg, Cora
    Patel, Amie
    Yuan, Sarah
    Fernandez, Escarleth
    Fung, Edward
    Avlonitis, Vasilios
    O'Dwyer, Elisabeth
    Nanus, David
    Osborne, Joseph
    Bander, Neil
    Tagawa, Scott
    JOURNAL OF UROLOGY, 2024, 211 (05): : E67 - E68
  • [5] Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Osborne, Joseph
    Fernandez, Escarleth
    Thomas, Charlene
    Niaz, Muhammad Junaid
    Ciriaco, Amy
    Vallabhajosula, Shankar
    Vlachostergios, Panagiotis J.
    Molina, Ana M.
    Sternberg, Cora N.
    Singh, Sharon
    Babich, John
    Nanus, David M.
    Ballman, Karla, V
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.
    Nauseef, Jones T.
    Sun, Michael Philip
    Thomas, Charlene
    Bissassar, Mahelia
    Patel, Amie
    Tan, Angela
    Fernandez, Escarleth
    Davidson, Zachary
    Chamberlain, Tessa
    Earle, Kara
    Wunder, Rebecca
    Castellanos, Sandra Huicochea
    Gregos, Peter
    Osborne, Joseph
    Ballman, Karla V.
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Phase I dose-escalation study of docetaxel/predisone and fractionated 177Lu-J591 for metastatic castrate-resistant prostate cancer (metCRPC)
    Beltran, H.
    Vallabhajosula, S.
    Kelly, W. K.
    Whang, Y. E.
    Osborne, J.
    Petrillo, K.
    Goldsmith, S. J.
    Bander, N. H.
    Nanus, D. M.
    Tagawa, S. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
    Tagawa, S. T.
    Vallabhajosula, S.
    Jhanwar, Y.
    Hackett, A.
    Oromendia, C.
    Naiz, M. J.
    Goldsmith, S. J.
    Nanus, D. M.
    Beltran, H.
    Molina, A. M.
    Faltas, B.
    Sreekumar, J.
    Babich, J.
    Ballman, K.
    Bander, N. H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591
    Tagawa, Scott T.
    Thomas, Charlene
    Sartor, A. Oliver
    Sun, Michael
    Stangl-Kremser, Judith
    Bissassar, Mahelia
    Vallabhajosula, Shankar
    Castellanos, Sandra Huicochea
    Nauseef, Jones T.
    Sternberg, Cora N.
    Molina, Ana
    Ballman, Karla
    Nanus, David M.
    Osborne, Joseph R.
    Bander, Neil H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (07) : 842 - 851
  • [10] Phase I study of 225Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).
    Tagawa, Scott T.
    Sun, Michael
    Sartor, A. Oliver
    Thomas, Charlene
    Singh, Sharon
    Bissassar, Mahelia
    Fernandez, Escarleth
    Niaz, Muhammad Junaid
    Ho, Benedict
    Vallabhajosula, Shankar
    Babich, John
    Molina, Ana M.
    Sternberg, Cora N.
    Nanus, David M.
    Osborne, Joseph
    Bander, Neil Harrison
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345